Rheumatoid arthritis is a disease caused by inflammation of the tissue that surrounds the joint called the synovium. The disorder can occur in any movable joint that has a synovial membrane. It is a chronic disease that progresses over months to years.

The exact cause of rheumatoid arthritis is unknown. However, thanks to advances in modern medicine, partial progress has been made. It is presumed that when a person genetically predisposed to rheumatoid arthritis receives some external stimulus, the body's immune system attacks the body abnormally and causes inflammation. In other words, rheumatoid arthritis is a type of autoimmune disease in which the body's immune system, which should play a defense against external bad bacteria, attacks its own body tissues.

Drugs for rheumatoid arthritis include primary drugs such as non-steroidal anti-inflammatory drugs and steroids and secondary drugs that suppress rheumatoid arthritis itself by affecting the body's immune system.

However, despite the existence of such an effective treatment, there are patients with rheumatoid arthritis recurrence and unresponsiveness, and safety issues for infection are being raised, so the demand for drug development with a new mechanism is high.

• According to Datamonitor Healthcare, the rheumatoid arthritis market (USA, Japan, France, Germany, Italy, Spain, UK) will grow from US$ 20.4 billion in 2018 to US$ 27.9 billion by 2027. It is expected to increase by about $7.5 billion, growing at a CAGR of 3.55%.
• The market share of rheumatoid arthritis treatment was 37% for Humira, followed by Enbrel at 14%, Rituxan at 13%, Remicade at 12%, and others at 24%. In the case of formulations, injections are expected to dominate from 2018 to 2027, but oral formulations such as Xeljanz (Pfizer) and Prograf (Astellas) account for 10.8% (2018). is expected to rise to 25.6% (by 2027).